NATICK, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today welcomed an article in the Journal of the
American Medical Association (JAMA) on the TAXUS V clinical trial that found
the TAXUS(R) Express2(TM) paclitaxel-eluting stent system significantly
reduces the risk of artery re-narrowing nine months following angioplasty for
patients with complex coronary artery lesions, compared to bare-metal stents.
The results of the study were published in the September 14th edition of JAMA.
The study (TAXUS V) showed that compared with bare-metal stents,
implantation of paclitaxel-eluting stents reduced the nine-month rate of
target lesion revascularization (the need for a repeat procedure in the
stented area) from 15.7 percent to 8.6 percent and target vessel
revascularization from 17.3 percent to 12.1 percent.
"The TAXUS V trial investigated the use of paclitaxel-eluting stents in a
patient population with more complex lesions than had been previously studied.
Angiographic restenosis and target vessel revascularization were significantly
reduced in the entire cohort, as well as in those patients with complex
disease," the authors wrote.
"The JAMA article is yet another impressive chapter in the evolving story
of Boston Scientific's paclitaxel-eluting stent program, adding to the science
of treating coronary artery disease in previously unstudied patients. No
other drug-eluting stent has been studied in such complex patients and
lesions," said Hank Kucheman, President of Boston Scientific's Interventional
Cardiology business. "With the recent introduction of TAXUS(R) Liberte(TM)
into Europe and other international markets, we begin the next chapter of this
compelling story. While The TAXUS Liberte stent system continues to feature
the proven safety and efficacy of paclitaxel, it introduces the first next-
generation drug-eluting stent in Liberte(TM), which dramatically raises the
bar in terms of stent deliverability and flexibility."
The study -- which included the use of multiple stents as well as single
stents -- included 1,172 patients and was designed to assess the safety and
efficacy of a paclitaxel-eluting coronary stent in reducing restenosis in de
novo lesions 10 - 46 mm in length and 2.25 - 4.0 mm in diameter. It had a
primary endpoint of nine-month target vessel revascularization.
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
http://www.bostonscientific.com.
This press release contains forward-looking statements. The Company
wishes to caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with clinical
trials, the regulatory approval process, commercialization of new
technologies, intellectual property, and other factors described in the
Company's filings with the Securities and Exchange Commission.
CONTACT:
Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation
Paul Donovan
508-650-8541
Media Relations
Boston Scientific Corporation
SOURCE Boston Scientific Corporation
 back to top
Related links:
http://www.bostonscientific.com
CONTACT:
Milan Kofol, +1-508-650-8569, Investor
Relations; or Paul Donovan, +1-508-650-8541, Media Relations,
both of Boston Scientific Corporation
|
